ES2073751T3 - Nuevo peptido con actividad fisiologica de origen porcino. - Google Patents
Nuevo peptido con actividad fisiologica de origen porcino.Info
- Publication number
- ES2073751T3 ES2073751T3 ES91908466T ES91908466T ES2073751T3 ES 2073751 T3 ES2073751 T3 ES 2073751T3 ES 91908466 T ES91908466 T ES 91908466T ES 91908466 T ES91908466 T ES 91908466T ES 2073751 T3 ES2073751 T3 ES 2073751T3
- Authority
- ES
- Spain
- Prior art keywords
- edema
- terminals
- physiological activity
- activities
- new peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 230000001766 physiological effect Effects 0.000 title 1
- 206010030113 Oedema Diseases 0.000 abstract 2
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 abstract 1
- 208000009304 Acute Kidney Injury Diseases 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000009447 Cardiac Edema Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 208000033626 Renal failure acute Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 208000020832 chronic kidney disease Diseases 0.000 abstract 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 abstract 1
- 239000002934 diuretic Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002440 hepatic effect Effects 0.000 abstract 1
- 230000001077 hypotensive effect Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000001452 natriuretic effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cardiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
SE PRESENTA UN NUEVO PEPTIDO REPRESENTADO POR LA FORMULA ESTRUCTURA (I) Y UNA SAL DE ADICCION ACIDA DEL MISMO EN LA QUE LOS TERMINALES 1 Y 2 ESTAN DIRECTAMENTE UNIDOS UNO A OTRO Y POR LO TANTO CONSTITUYEN LOS TERMINALES 3 Y 4, Y LOS RESIDUOS DE CISTEINA (CIS) EN LAS POSICIONES 6INTRAMOLECULAR. DESDE EL MOMENTO QUE EL PEPTIDO PRESENTA ACTIVIDADES NATRIURETICAS E HIPOTENSORAS, ES UTIL PARA EL TRATAMIENTO DEL EDEMA CARDIACO, EL EDEMA RENAL, EL EDEMA HEPATICO, LA HIPERTENSION, EL FALLO CONGESTIVO, Y LA INSUFICIENCIA RENAL AGUDA Y CRONICA. COMO TAMBIEN PRESENTA ACTIVIDADES DE INHIBICION DEL CRECIMIENTO DE LAS CELULAS DEL MUSCULO VASCULAR Y PRODUCE CGMP, SE ESPERA QUE SEA BENEFICIOSO CONTRA LA ARTERIOSCLEROSIS.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP10504790 | 1990-04-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2073751T3 true ES2073751T3 (es) | 1995-08-16 |
Family
ID=14397086
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES91908466T Expired - Lifetime ES2073751T3 (es) | 1990-04-20 | 1991-04-20 | Nuevo peptido con actividad fisiologica de origen porcino. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US5352770A (es) |
| EP (1) | EP0478797B1 (es) |
| JP (1) | JP2636500B2 (es) |
| AT (1) | ATE121102T1 (es) |
| DE (1) | DE69108830T2 (es) |
| DK (1) | DK0478797T3 (es) |
| ES (1) | ES2073751T3 (es) |
| GR (1) | GR3015762T3 (es) |
| WO (1) | WO1991016342A1 (es) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2809533B2 (ja) * | 1991-01-31 | 1998-10-08 | 壽之 松尾 | Ｃｎｐ類似体ペプチド |
| BRPI0203172B8 (pt) | 2001-09-28 | 2021-05-25 | Nakao Kazuwa | composição farmacêutica para acondroplasia |
| US20080214437A1 (en) * | 2002-09-06 | 2008-09-04 | Mohapatra Shyam S | Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases |
| US7488713B2 (en) * | 2004-03-18 | 2009-02-10 | University Of South Florida | Cancer treatment using C-type natriuretic peptides |
| US8759317B2 (en) * | 2004-03-18 | 2014-06-24 | University Of South Florida | Method of treatment of cancer using guanosine 3′, 5′ cyclic monophosphate (cyclic GMP) |
| ES2465141T3 (es) | 2004-03-31 | 2014-06-05 | Kazuwa Nakao | Remedio o medicamento preventivo para la artritis |
| WO2005094890A1 (ja) | 2004-03-31 | 2005-10-13 | Kazuwa Nakao | 身長増加用組成物 |
| CA2559228C (en) | 2004-04-21 | 2016-06-21 | Enobia Pharma Inc. | Bone delivery conjugates and method of using same to target proteins to bone |
| EP2023950B1 (en) * | 2006-05-05 | 2012-07-11 | University of South Florida | Urodilatin cancer treatment |
| EP2217620A2 (en) * | 2007-11-21 | 2010-08-18 | BioMarin Pharmaceutical Inc. | Variants of c-type natriuretic peptide |
| PT2432489T (pt) | 2009-05-20 | 2016-12-07 | Biomarin Pharm Inc | Variantes do péptido natriurético de tipo c |
| WO2012088608A1 (en) | 2010-12-27 | 2012-07-05 | Enobia Canada Limited Partnership | Compositions comprising natriuretic peptides and methods of use thereof |
| US10184942B2 (en) | 2011-03-17 | 2019-01-22 | University Of South Florida | Natriuretic peptide receptor as a biomarker for diagnosis and prognosis of cancer |
| KR20140084201A (ko) | 2011-10-19 | 2014-07-04 | 알렉시온 파마 홀딩 | 알칼리성 포스파타제 및/또는 나트륨이뇨 펩티드를 포함하는 조성물 및 그의 사용 방법 |
| ITRM20120060A1 (it) * | 2012-02-21 | 2013-08-22 | Consiglio Nazionale Ricerche | Peptidi in grado di dissociare lo eterodimero mdm2/mdm4 e loro uso nel trattamento del cancro. |
| US10052366B2 (en) | 2012-05-21 | 2018-08-21 | Alexion Pharmaceuticsl, Inc. | Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof |
| WO2016007873A1 (en) | 2014-07-11 | 2016-01-14 | The Regents Of The University Of Michigan | Compositions and methods for treating craniosynostosis |
| MX389350B (es) | 2014-12-05 | 2025-03-19 | Alexion Pharma Inc | Fosfatasas alcalinas recombinantes y usos de las mismas para el tratamiento de convulsiones. |
| JP6868561B2 (ja) | 2015-01-28 | 2021-05-12 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | アルカリホスファターゼ欠損を有する被験者を治療する方法 |
| DK3328416T5 (da) | 2015-07-30 | 2024-10-07 | Biomarin Pharm Inc | Anvendelse af natriuretske peptidvarianter af c-typen til behandling af skeletdysplasi |
| CN108350440A (zh) | 2015-08-17 | 2018-07-31 | 阿雷克森制药公司 | 碱性磷酸酯的制造 |
| JP6868617B2 (ja) | 2015-09-28 | 2021-05-12 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 低ホスファターゼ血症の組織非特異的アルカリホスファターゼ（ｔｎｓａｌｐ）酵素補充療法に有効な投薬計画の特定 |
| JP2018533571A (ja) | 2015-10-30 | 2018-11-15 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 患者の頭蓋縫合早期癒合症を治療するための方法 |
| WO2017155569A1 (en) | 2016-03-08 | 2017-09-14 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia in children |
| US10898549B2 (en) | 2016-04-01 | 2021-01-26 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia in adolescents and adults |
| JP7613826B2 (ja) | 2016-04-01 | 2025-01-15 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | アルカリホスファターゼによって筋力低下を治療すること |
| US10988744B2 (en) | 2016-06-06 | 2021-04-27 | Alexion Pharmaceuticals, Inc. | Method of producing alkaline phosphatase |
| EP3500289B1 (en) | 2016-08-18 | 2024-10-09 | Alexion Pharmaceuticals, Inc. | Asfotase alfa for use in treating tracheobronchomalacia |
| EP3600383A4 (en) | 2017-03-31 | 2020-10-28 | Alexion Pharmaceuticals, Inc. | METHODS OF TREATMENT OF HYPOPHOSPHATASIA (HPP) IN ADULTS AND ADOLESCENTS |
| US11913039B2 (en) | 2018-03-30 | 2024-02-27 | Alexion Pharmaceuticals, Inc. | Method for producing recombinant alkaline phosphatase |
| US12268733B2 (en) | 2018-08-10 | 2025-04-08 | Alexion Pharmaceuticals, Inc. | Methods of treating neurofibromatosis type 1 and related conditions with alkaline phosphatase |
| US20230192799A1 (en) | 2019-09-16 | 2023-06-22 | Biomarin Pharmaceutical Inc. | CNP Variants and Conjugates Thereof |
| CA3161266A1 (en) | 2019-12-09 | 2021-06-17 | Alexion Pharmaceuticals, Inc. | Alkaline phosphatase polypeptides and methods of use thereof |
| AU2021337652B2 (en) | 2020-09-04 | 2025-01-30 | Alexion Pharmaceuticals, Inc. | Methods for treating bone mineralization disorders |
| BR112023016048A2 (pt) | 2021-02-12 | 2023-11-14 | Alexion Pharma Inc | Polipeptídeos de fosfatase alcalina e métodos de uso dos mesmos |
| MX2024000526A (es) | 2021-07-09 | 2024-02-02 | Biomarin Pharm Inc | Variantes del peptido natriuretico tipo c para tratar la displasia esqueletica en ni?os. |
| EP4444341A1 (en) | 2021-12-07 | 2024-10-16 | BioMarin Pharmaceutical Inc. | C-type natriuretic peptide therapy of bone-related disorders |
| WO2024094747A1 (en) | 2022-11-02 | 2024-05-10 | Novo Nordisk A/S | Cnp compounds |
| CN121889516A (zh) | 2023-06-07 | 2026-04-17 | 生物马林药物股份有限公司 | 用于与身材矮小相关的遗传变体的高通量筛选 |
| TW202535449A (zh) | 2023-11-08 | 2025-09-16 | 美商拜奧馬林製藥公司 | Ｃｎｐ變異體、其接合物及調配物 |
| WO2026030743A1 (en) | 2024-08-02 | 2026-02-05 | Biomarin Pharmaceutical Inc. | Treatment of short stature with cnp variants |
-
1991
- 1991-04-20 ES ES91908466T patent/ES2073751T3/es not_active Expired - Lifetime
- 1991-04-20 WO PCT/JP1991/000527 patent/WO1991016342A1/ja not_active Ceased
- 1991-04-20 DE DE69108830T patent/DE69108830T2/de not_active Expired - Lifetime
- 1991-04-20 JP JP3507547A patent/JP2636500B2/ja not_active Expired - Lifetime
- 1991-04-20 EP EP91908466A patent/EP0478797B1/en not_active Expired - Lifetime
- 1991-04-20 US US07/778,847 patent/US5352770A/en not_active Expired - Lifetime
- 1991-04-20 AT AT91908466T patent/ATE121102T1/de not_active IP Right Cessation
- 1991-04-20 DK DK91908466.5T patent/DK0478797T3/da active
-
1995
- 1995-04-13 GR GR940403144T patent/GR3015762T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP0478797A1 (en) | 1992-04-08 |
| DE69108830T2 (de) | 1995-09-14 |
| DE69108830D1 (de) | 1995-05-18 |
| EP0478797A4 (en) | 1993-09-01 |
| ATE121102T1 (de) | 1995-04-15 |
| JP2636500B2 (ja) | 1997-07-30 |
| US5352770A (en) | 1994-10-04 |
| GR3015762T3 (en) | 1995-07-31 |
| DK0478797T3 (da) | 1995-06-26 |
| WO1991016342A1 (fr) | 1991-10-31 |
| EP0478797B1 (en) | 1995-04-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2073751T3 (es) | Nuevo peptido con actividad fisiologica de origen porcino. | |
| TW357146B (en) | Tetrahydrofuran antifungals | |
| RU94018226A (ru) | Метансульфонат (е)-3-/2-н-бутил-1-//4-карбоксифенил/метил/-1н-имидазол-5-ил/-2-/2-тиенил/метил-2-пропеновой кислоты, способ его получения, фармацевтическая композиция на его основе | |
| DK0730470T3 (da) | Forbedrede interferonpolymerkonjugater | |
| DK0415456T3 (da) | Xanthinforbindelser | |
| NZ233546A (en) | Azelastine salts with improved solubility | |
| FI906296A0 (fi) | Nya metylenbisfosfonsyrederivat. | |
| DE3480828D1 (de) | Antivirale zusammensetzungen. | |
| RU97105438A (ru) | Глазные капли "неокератоник" | |
| TW200510369A (en) | Novel ethylenediamine derivatives | |
| EP0269220A3 (en) | Derivatives of alpha-hanp and their production | |
| EP0159040A3 (en) | Pyridine derivatives and production thereof | |
| FI943808A0 (fi) | Triatsolopyrimidiinijohdannaisia angiotensiini II:n reseptoreiden vastavaikuttajina | |
| ES8502435A1 (es) | Un metodo para preparar 2(1h)-piridinonas | |
| EA199800035A1 (ru) | Способ получения производных дифенила и промежуточное для получения дифенила | |
| MX9604019A (es) | Derivados de biotina. | |
| DK1214323T3 (da) | Indoloazepiner som vasopressinreceptorantagonister | |
| GB1447827A (en) | Benzimidazole derivatives | |
| ATE34983T1 (de) | Indolderivate. | |
| ES8502694A1 (es) | Procedimiento para preparar 1,3,4-benzotriazepinas sustituidas. | |
| RO91712B1 (ro) | Solutie injectabila cu actiune coronarodilatoare si antihipertensiva | |
| IT1188571B (it) | Procedimento per la produzione di bussole a struttura perfezionata,per l'unione di parti in legno | |
| UA25289C2 (uk) | Спосіб приготування горілки "імператорська" | |
| RU92004387A (ru) | Триаргинининсулины | |
| ES2179967T3 (es) | Procedimiento de preparacion de compuestos 3-hidroxilados que contienen un heterociclo de seis eslabones. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG2A | Definitive protection |
Ref document number: 478797 Country of ref document: ES |